Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.

Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, Mujais SK, Schaddelee MP, de Koning P, Kaibara A, Moy SS, Keirns JJ.

Clin Pharmacol Ther. 2012 Dec;92(6):696-706. doi: 10.1038/clpt.2012.181. Epub 2012 Nov 14.

PMID:
23149929
2.

Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.

de Kam PJ, van Kuijk J, Smeets J, Thomsen T, Peeters P.

Int J Clin Pharmacol Ther. 2012 Aug;50(8):595-604. doi: 10.5414/CP201693.

PMID:
22735462
3.

Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.

de Kam PJ, van Kuijk J, Prohn M, Thomsen T, Peeters P.

Clin Drug Investig. 2010;30(9):599-611. doi: 10.2165/11537210-000000000-00000.

PMID:
20568829
4.
5.

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

Matz J, Graff C, Vainio PJ, Kallio A, Højer AM, Struijk JJ, Kanters JK, Andersen MP, Toft E.

Clin Drug Investig. 2011 Nov 1;31(11):799-811. doi: 10.2165/11592950-000000000-00000.

PMID:
21967071
6.

Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.

Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M.

Clin Ther. 2012 Oct;34(10):2144-60. doi: 10.1016/j.clinthera.2012.09.010.

PMID:
23063375
7.

Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.

Hofmann C, Banken L, Hahn M, Swearingen D, Nagel S, Martin-Facklam M.

Clin Ther. 2012 Oct;34(10):2061-71. doi: 10.1016/j.clinthera.2012.08.010. Epub 2012 Sep 12.

PMID:
22980315
8.

Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.

Morganroth J, Gretler DD, Hollenbach SJ, Lambing JL, Sinha U.

Expert Opin Pharmacother. 2013 Jan;14(1):5-13. doi: 10.1517/14656566.2013.753057. Epub 2012 Dec 10.

PMID:
23216423
9.

Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study.

Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A.

Eur J Clin Pharmacol. 2007 Nov;63(11):1011-7. Epub 2007 Sep 21.

PMID:
17891537
10.

Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.

Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A.

Clin Ther. 2008 Feb;30(2):260-70. doi: 10.1016/j.clinthera.2008.02.002.

PMID:
18343264
11.

Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.

Zhang W, Smulders R, Abeyratne A, Dietz A, Krauwinkel W, Kadokura T, Keirns J.

Clin Ther. 2013 Aug;35(8):1150-1161.e3. doi: 10.1016/j.clinthera.2013.06.009. Epub 2013 Aug 2.

PMID:
23910665
12.

Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study.

Green CL, Whellan DJ, Lambe L, Bellibas SE, Wijngaard P, Prats J, Krucoff MW.

J Cardiovasc Pharmacol. 2013 Nov;62(5):466-78. doi: 10.1097/FJC.0b013e3182a2630d.

PMID:
23921301
13.

Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.

Davy M, Upward J, Arumugham T, Twomey C, Chen C, Stier B.

Clin Ther. 2013 Dec;35(12):1964-74. doi: 10.1016/j.clinthera.2013.10.011. Epub 2013 Nov 28.

PMID:
24290737
14.

A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.

Mansbach RS, Ludington E, Rogowski R, Kittrelle JP, Jochelson P.

Clin Ther. 2011 Jul;33(7):851-62. doi: 10.1016/j.clinthera.2011.05.092. Epub 2011 Jul 1.

PMID:
21722958
15.

Effect of intravenous zanamivir on cardiac repolarization.

Lou Y, Gan J, Peppercorn A, Gould E, Weller S, Piscitelli SC, Patel P.

Pharmacotherapy. 2013 Jul;33(7):701-9. doi: 10.1002/phar.1261. Epub 2013 Apr 3.

PMID:
23553534
16.

Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.

Chen S, Min SS, Peppercorn A, Borland J, Lou Y, Song I, Fujiwara T, Piscitelli SC.

Pharmacotherapy. 2012 Apr;32(4):333-9. doi: 10.1002/j.1875-9114.2012.01033.x. Epub 2012 Mar 15.

PMID:
22422361
17.

Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers.

Taubel J, Naseem A, Wang D, Arezina R, Lorch U, Camm AJ.

Br J Clin Pharmacol. 2012 Aug;74(2):296-303. doi: 10.1111/j.1365-2125.2012.04190.x.

18.

No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.

Donado E, Izquierdo I, Pérez I, García O, Antonijoan RM, Gich I, Solans A, Peña J, Morganroth J, Barbanoj MJ.

Br J Clin Pharmacol. 2010 Apr;69(4):401-10. doi: 10.1111/j.1365-2125.2009.03599.x.

19.

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.

Shakeri-Nejad K, Aslanis V, Veldandi UK, Mooney L, Pezous N, Brendani B, Juan A, Allison M, Perry R, Legangneux E.

Clin Ther. 2015 Nov 1;37(11):2489-2505.e2. doi: 10.1016/j.clinthera.2015.09.006. Epub 2015 Oct 27.

PMID:
26519230
20.

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.

Darpö B, Sager P, MacConell L, Cirincione B, Mitchell M, Han J, Huang W, Malloy J, Schulteis C, Shen L, Porter L.

Br J Clin Pharmacol. 2013 Apr;75(4):979-89. doi: 10.1111/j.1365-2125.2012.04416.x.

Supplemental Content

Support Center